Recent results have shown that nintedanib induces apoptosis in triple-negative breast cancer cells by inhibiting the phosphorylation of STAT3 [19] and inhibits the tumor growth of malignant pleural mesothelioma (MPM) via blockade of angiogenesis [20]. This evidence concerns the gene STAT3 and triple-negative breast carcinoma.